BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Lisata Therapeutics readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Lisata Therapeutics's drugs run\,
  from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07028749-1200@assetmemo.bio
DTSTAMP:20261121T005726Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:MAR001: Phase 2 readout est. (NCT07028749)
DESCRIPTION:MAR001\, phase 2\, Hypertriglyceridemia.\nStudy: Study of MAR00
 1 in Adults With Elevated Triglycerides and Remnant Cholesterol\nEstimated
  primary completion: November 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/mar001#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07028749
URL:https://assetmemo.bio/drug/mar001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
